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Abstract
Background: Laboratory assays are needed for early stage non-small lung cancer (NSCLC) that can link molecular
and clinical heterogeneity to predict relapse after surgical resection. We technically validated two miRNA assays for
prediction of relapse in NSCLC. Total RNA from seventy-five formalin-fixed and paraffin-embedded (FFPE)
specimens was extracted, labeled and hybridized to Affymetrix miRNA arrays using different RNA input amounts,
ATP-mix dilutions, array lots and RNA extraction- and labeling methods in a total of 166 hybridizations. Two
combinations of RNA extraction- and labeling methods (assays I and II) were applied to a cohort of 68 early stage
NSCLC patients.
Results: RNA input amount and RNA extraction- and labeling methods affected signal intensity and the number of
detected probes and probe sets, and caused large variation, whereas different ATP-mix dilutions and array lots did
not. Leave-one-out accuracies for prediction of relapse were 63% and 73% for the two assays. Prognosticator calls
("no recurrence” or “recurrence”) were consistent, independent on RNA amount, ATP-mix dilution, array lots and
RNA extraction method. The calls were not robust to changes in labeling method.
Conclusions: In this study, we demonstrate that some analytical conditions such as RNA extraction- and labeling
methods are important for the variation in assay performance whereas others are not. Thus, careful optimization
that address all analytical steps and variables can improve the accuracy of prediction and facilitate the introduction
of microRNA arrays in the clinic for prediction of relapse in stage I non-small cell lung cancer (NSCLC).
Background
Early stage non-small cell lung (NSCLC) cancer is char-
acterized by both clinical and molecular genetic hetero-
geneity with five-year recurrence and survival rates of
50% and 73% respectively [1]. Although several rando-
mized studies have been performed, the use of adjuvant
chemotherapy for stage I NSCLC still is controversial
[2] and surgical resection remains the primary treatment
for this disease.
However, in spite of tumor heterogeneity, new techni-
ques in molecular profiling [3-5] can supplement clinical
and pathologic observations and help to identify patients
with a particularly poor prognosis. This can be useful
both for intensified follow-up and for administering
therapy specifically to patients at a high risk of recur-
rence [6].
In this study, we performed global microarray expres-
sion profiling targeting several small non-coding RNA
species including microRNAs (miRNAs). MicroRNAs
are small noncoding RNAs of approximately 18-25
nucleotides in length that regulate gene expression at
the post transcriptional level by base pairing with
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mRNA, leading to either translational repression [7], or
mRNA degradation [8-10]. MicroRNAs have been esti-
mated to regulate up to 30% of all human genes [11],
and frequently reside in cancer associated genomic
regions [12]. Deregulation of miRNA expression plays a
direct role in oncogenesis, and in differentiation and
progression in cancer, in part because deregulation can
change the expression of oncogenes and tumour sup-
pressor genes [13]. Strong deregulation of miRNA
expression has been seen in several forms of cancer,
including lung carcinoma [4], and several studies have
suggested that miRNA profiling can be used for prog-
nostication in lung cancer [3-6].
The enhanced stability of microRNAs in contrast to
mRNAs, allow expression profiling in routinely stored
formalin-fixed and paraffin-embedded (FFPE) specimens,
including samples that are more than ten years old [14].
Large FFPE archives exist in diagnostic pathology
departments throughout the world. When linked to clin-
ical data, they represent an invaluable biobank resource
for exploring the association between molecular changes
in tumors and clinical endpoints such as relapse or sur-
vival after surgery. Furthermore in the case of early
stage NSCLC, FFPE specimens will be available for most
patients. Therefore, it is realistic to use miRNAs and
non-coding RNAs as biomarkers for prognosis in stage I
NSCLC, once a prognostic signature has been clinically
validated.
In order to reach this goal, carefully conducted studies
are needed [15,16], incorporating well defined experi-
mental procedures that may eventually lead to the
development of clinically validated applications allowing
for individual treatment strategies in early stage NSCLC.
Previously, the Microarray Quality Control (MAQC)
study [17] focused on the entire process from sample
handling, through laboratory and assay conditions, to
data normalization and bioinformatics. This demon-
strated the scope and significant potential of microarray
technology for the clinic [18] when performed under
careful and well-defined experimental conditions.
In this study, we compared two laboratory assays for
prognostication in stage I NSCLC based on miRNA pro-
filing in FFPE tissue specimens. To perform an objective
evaluation [16], of the different reagents, array products
and protocols we examined several analytical conditions
(figure 1) including: i) 7 different RNA input amounts
using one RNA preparation of a single tumor specimen,
ii) three different ATP-mix dilutions using two RNA
preparations of two tumor specimens, iii) two different
array lot numbers using one RNA preparation of a sin-
gle tumor specimen, iv) two different RNA extraction
kits using eight RNA preparations of four tumor speci-
mens, and, v) two different RNA labeling kits using four
RNA preparations of four tumor specimens in 8 labeling
reactions. In addition, RNA was extracted twice from
the same specimens in a cohort of more than 60
NSCLC patients in a direct comparison of the two
assays. Thus, 139 RNA extractions and 166 hybridiza-
tions were performed from a total of 75 NSCLC speci-
mens. To qualify the impact of any variation in the
assay specific analytical conditions, principal component
analysis was performed. In addition, prognosticator calls
(i.e. “recurrence” or “no recurrence”) was examined after
varying the analytical conditions for selected samples.
Results
RNA input amount
A linear regression model showed that the amount of
purified small RNA used for hybridization significantly
affected mean signal intensity; the number of detected
probes; and the number of detected probe sets (bsignal =
0.03 ± 0.01, t = 2.6, p < 0.05, R2 = 0.58; bprobes = 3.64 ±
0.60, t = 6.0, p < 0.01, R2 = 0.88; bprobe sets = 0.94 ± 0.12,
t = 7.6, p < 0.001, R2 = 0.88; figure 2, 3 and 4). The
amount of total RNA used for hybridization also
affected the number of detected probes (mean100 ng =
Tissue sample (NSCLC) from 
FFPE specimen with >70% 
tumor cell content 
RNA isolation  
-High Pure (HP) vs. RecoverAll (RA)
5’ 3’ 
Labelling 
-RNA input amount 
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-FlashTag vs. FlashTagHSR 
Hybridization and scanning 
-Chip lot number 
Figure 1 Work-flow starting by securing the tumor tissue from
the FFPE specimen and ending by scanning the array,
including the different analytical variables under study: i) RNA
extraction kit, ii) RNA input amount, iii) ATP-mix dilution, iv) RNA
labeling kit, and v) chip lot number.
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3674 vs. mean600 ng = 4627, t = -2.04, df = 18, p = 0.05;
figure 5) and the number of detected probe sets
(mean100 ng = 803 vs. mean600 ng = 1134, t = -2.41, df =
18, p < 0.05; figure 6). Self-self correlations in probe sig-
nal intensities between arrays hybridized to different
amounts of the same RNA preparation varied across
different combinations of RNA input amount (table 1).
In addition, a linear regression analysis revealed that
self-self correlations in probe signal intensities decreased
when ratios in RNA input amounts between pairs
increased, considering all pair wise combinations (bDevR-
NAinput = -0.0042 ± 0.0004, t = -10.0, p < 0.001, R
2 =
0.95; figure 7).
ATP-mix dilution
The effect of ATP-mix dilution was not significant in a
linear regression model (results not shown), when ana-
lyzing six hybridizations with RNA from two NSCLC
specimens, each labeled using three different ATP-mix
dilutions. Thus, mean signal intensity, background
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Figure 2 Mean signal intensity using varying input amounts
(ng) of small RNA from an NSCLC T2 tumor that was preserved
in RNAlater within 2 hours of surgery.
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Figure 3 Number of detected probes using varying input
amounts (ng) of small RNA from an NSCLC T2 tumor that was
preserved in RNAlater within 2 hours of surgery.
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Figure 4 Number of detected probe sets using varying input
amounts (ng) of small RNA from an NSCLC T2 tumor that was
preserved in RNAlater within 2 hours of surgery.






































	





	

	

	

Figure 5 Number of detected probes in hybridizations where
tumor samples were labeled using either 100 ng or 600 ng
total RNA.
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intensity, the numbers of detected probes, and the num-
bers of detected probe sets were stable across the tested
range (table 2). Self-self correlations coefficients in
probe signal intensities between arrays with RNA
labeled at different ATP-mix dilutions were invariant
across the tested range (table 3). Thus, there were no
association between self-self correlations and the ratio
of ATP-mix dilutions among arrays hybridized to RNA
labeled at different ATP-mix dilutions, considering all
pair wise combinations (results not shown).
Different chip lot numbers
Hybridizations (in triplicates) with labeled RNA from a
single T2 NSCLC tumor revealed that signal intensity
and the number of probes and probe sets were not sig-
nificantly different across different lot numbers (results
not shown). In addition, the observed self-self correla-
tion coefficient across probe signal intensities within
and between lots did not vary (table 4). In particular, the
self-self correlation coefficient across probe signal inten-
sities within one lot of arrays (cc = 0.973) was similar to
the estimated average correlation between two different
lots of arrays (cc = 0.965; 95% C.I. = 0.92-1.01).
Comparisons of two different RNA extraction kits
Mean intensity ± se (xRecoverAll = 247.7 ± 26.9 vs. xHigh-
Pure = 190.1 ± 8.2), the number of detected probes ± se
(xRecoverAll = 9407.8 ± 98.0 vs. xHighPure = 7733.5 ±
671.1) and the number of detected probe sets ± se (xRe-
coverAll = 2328.8 ± 27.9 vs. xHighPure = 2088.5 ± 150.0) in
hybridizations with total RNA extracted using the RA
kit all exceeded that for the HP kit (figure 8 and 9),
although this was significant only for the numbers of
detected probes (ANOVA; F1,6 = 6.09, P < 0.05). Back-
ground intensity was not significantly different between
the kits (xRecoverAll = 56.3 ± 2.5 vs. xHighPure = 51.7 ±
2.0; figure 8). PCA, considering the expression of all
human ncRNAs, as well as that of a specific miRNA sig-
nature for prognostication, demonstrated that a major
proportion of the variance could be assigned to the two
RNA extraction methods (i.e. between-kit variance) as
revealed by the first principal component (PC1; figure
10 and 11).
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Figure 6 Number of detected probe sets in hybridizations
where tumor samples were labeled using either 100 ng or 600
ng total RNA.
Table 1 Correlations in signal intensities across probes
from different arrays that were hybridized to four
different amounts of RNA (ATP-mix dilution, 1:50) from a
single preparation of a T2 NSCLC tumor.
RNA amount 80 ng 160 ng 400 ng 640 ng
80 ng - 0.976 0.964 0.953
160 ng - - 0.974 0.968
400 ng - - - 0.983
640 ng - - - -
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Figure 7 Linear regression analysis revealed that self-self
correlations in probe signal intensities between arrays
hybridized to different amounts of RNA from an NSCLC T2
tumor (preserved in RNAlater) decreased when deviations in
RNA amounts between pairs increased, considering all pair
wise combinations (bDevRNAinput = 0.0002 ± 0.00002, t = -11.7, p
< 0.001, R2 = 0.96).
Table 2 Mean( ± SEM) signal intensity, background
intensity, number of detected probes and number of
detected probe sets in hybridizations using 600 ng RNA
from two NSCLC specimens (duplicates) each labeled
using three different ATP-mix dilutions (1:50; 1:150 and
1:500).
ATP-mix dilution 1:50 1:150 1:500
Mean Intensity 349 ± 27 339 ± 19 351 ± 9
Mean Background Intensity 89.3 ± 0.5 97.6 ± 4.6 92.3 ± 3.7
Number of Detected Probes 9762 ± 213 9378 ± 435 9585 ± 139
Number of Detected Probe Sets 2432 ± 28 2382 ± 101 2371 ± 12
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Comparisons of two different RNA labeling kits
For hybridizations with RNA labeled using the FlashTag
Biotin HSR labeling kit; mean intensity (x ± se FlashTag
HSR = 215.1 ± 18.1 vs. x ± se FlashTag = 68.3 ± 2.9;
ANOVA; F1,6 = 64.4, P < 0.001), the numbers of
detected probes (x ± se FlashTag HSR = 8153 ± 302 vs. x ±
se FlashTag= 6079 ± 323; ANOVA; F1,6 = 21.9, P < 0.01)
and the numbers of detected probe sets (x ± se FlashTag
HSR = 2139 ± 87 vs. x ± se FlashTag= 1527 ± 61;
ANOVA; F1,6 = 33.5, P < 0.01), all exceeded those in
hybridizations with RNA labeled using the FlashTag
Biotin labeling kit (figure 12 and 13). Background inten-
sity was significantly different between the kits (x ± se
FlashTag HSR = 77.6 ± 8.0 vs. x ± se FlashTag= 34.8 ± 0.9;
ANOVA; F1,6 = 28.1, P < 0.01). A major proportion of
the variance could be assigned to the different labeling
methods (between-kit variance) as revealed by PC1 in
the PCA (figure 14 and 15). PCA also revealed that the
variance for samples labeled with the old labeling meth-
ods was very small (compressed).
Assay I and II for prognostication in stage I NSCLC
samples
By performing 1000 Monte Carlo simulations we
obtained a prognostic accuracy of 60.0% (95% C.I.:
59.5% - 60.5%) for assay I and 62.6% (95% C.I.: 61.9% -
63.2%) for assay II (p = 9.82e-10 for the hypothesis that
the accuracy is similar for the two assays). Nested
LOOCV that optimized the number of selected non-
coding RNAs in a separate loop resulted in an LOOCV
accuracy of 63% for assay I and 73% for assay II. A mul-
tivariate analysis examined for the effects of the miRNA
chip based prognosis (i.e. “recurrence” or “no
recurrence”), age, smoking status, stage (Ia or Ib) and
histology (squamous or adeno) on recurrence after sur-
gery. Only the miRNA based prognosticator was signifi-
cant (PmiRNA Prognosis = 0.009; PAge = 0.656, PSmoking =
0.146, PStage = 0.921, PHistology = 0.732). Figure 16 shows
the predictions against a Kaplan-Meier time-to recur-
rence plot (LOOCV accuracy of 73%, p < 0.001). The
two miRNA lists obtained did not overlap and the list
obtained from one assay could not predict the other
assay.
Impact of the analytical conditions on the robustness of
the prognosticator
Prognosticator calls (i.e. “recurrence” or “no recur-
rence”) were consistent independent of the RNA
amount, ATP-mix dilution, chip lot number and RNA
extraction method being used. In contrast, the calls
were not robust to changes in labeling method (table 5).
Table 3 Self-self correlations (± SD) in signal intensities
across probes in six hybridizations using 600 ng RNA
from two NSCLC specimens with each specimen labeled
with three different ATP-mix dilutions (1:50; 1:150 and
1:500).
ATP-mix dilution 1:50 1:150 1:500
1:50 - 0.990 ± 0.001 0.990 ± 0.0
1:150 - - 0.989 ± 0.001
1:500 - - -
Table 4 Correlations in signal intensities across probes
from two different lots of arrays that were hybridized (in
triplicates) to 100 ng of labeled RNA (ATP-mix dilution
1:50) from of a single RNA preparation of a T2 NSCLC
tumor.
Array Chip 1, Lot “A” Chip 2, Lot “A” Chip 3, Lot “B”
Chip 1, Lot “A” - 0.973 0.968
Chip 2, Lot “A” - - 0.961
Chip 3, Lot “B” - - -
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Figure 8 Mean signal and background intensities in
hybridizations using RNA prepared from four tumor samples
using both the HighPure and RecoverAll RNA extraction kits
for FFPE studies.
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Figure 9 Number of detected probes and probe sets in
hybridizations using RNA prepared from four tumor samples
using both the HighPure and RecoverAll RNA extraction kits
for FFPE studies.
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Discussion
Validation of a microarray based laboratory assay poses
two technical challenges; first, ensuring that data are
aquired with the best laboratory proficiency; and second,
that data are analyzed appropriately. In order for a chip
based prognostic assay to be practically usefull and
accurate for prognostication in NSCLC, concern must
be adressed towards the concordance of expression
measurements and the impact of variation across analy-
tical conditions. Here we assessed the impact of varia-
tion in several analytical conditions including varying
RNA input amount, ATP-mix dilution, chip lot num-
bers, RNA extraction- and RNA labeling kit.
RNA input amount
Increasing the input RNA amounts led to an increase in
mean signal intensity and the number of detected
probes and probe sets (figure 2, 3, 4 and 5). Since no
amplification step is applied in either of the labeling kits
under test, this finding is expected. Also, as deviations
in RNA input amounts affected self-self correlations,
concern should be addressed to avoid large variations in
the amount of input RNA in similar miRNA based
laboratory assays (figure 7).
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Figure 10 PCA for all human non-coding RNAs in
hybridizations using RNA prepared from four tumor samples
using both the HighPure (Roche) and RecoverAll (Ambion) RNA
extraction kits for FFPE studies. “HP” (green) represents samples
extracted using HighPure (Roche), and, “RA” (red) represents the
same samples extracted using RecoverAll (Ambion).
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Figure 11 PCA for a 12 gene signature for prognosis in NSCLC in
hybridizations using RNA prepared from four tumor samples
using both the HighPure (Roche) and RecoverAll (Ambion) RNA
extraction kits for FFPE studies. “HP” (green) represents samples
extracted using HighPure (Roche), and, “RA” (red) represents the same
samples extracted using RecoverAll (Ambion).
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Figure 12 Mean signal and background intensities in
hybridizations using RNA from four tumor samples labeled
with the FlashTag Biotin- and FlashTag Biotin HSR labeling kits.
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Figure 13 Number of detected probes and probe sets in
hybridizations using RNA from four tumor samples labeled
with the FlashTag Biotin- and FlashTag Biotin HSR labeling kits.
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ATP-mix dilution
When 600 ng RNA (obtained with the RA kit) was used
as input in labeling reactions, ATP-mix dilutions did
not significantly affect mean signal intensity and the
number of detected probes and probe sets. Self-self cor-
relations in probe signal intensities between arrays were
also not affected by changing ATP-mix dilutions (table
3). Thus experimental variation in ATP-mix dilutions
appear to have no impact.
Different chip lot numbers
Correlations in signal intensities (table 4) were not
affected by different lot numbers of arrays. This result
was anticipated in part due to the In Vitro Diagnostics
status of the Affymetrix gene array scanner being used
here. In addition, Wen et al. [19] have demonstrated
that even for arrays that were expired by several years
(and of different lot numbers) the percentage of overlap
between lists of differentially expressed genes from the
expired and unexpired microarrays was 96.99%. In addi-
tion, microarray data generated using the expired micro-
arrays were highly concordant with microarray and
TaqMan® data generated by the MAQC project several
years before [19].
Comparison of the HighPure and RecoverAll purification
kits for FFPE studies
Mean intensity and the number of detected probes and
probe sets, in RNA preparations from the RA extraction
kit, all exceed that detected in RNA preparations
obtained from the HP extraction kit. This is consistent
with previous findings [14], showing that miRNA
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expression signals may be reduced when RNA is
extracted using the HighPure miRNA isolation kit
(Roche). Doleshal et al. [14], compared five different
miRNA extraction kits and concluded that three of the
kits showed two- to three-fold lower total RNA yield,
and five- to 20-fold lower miRNA qRT-PCR signals at
equal RNA mass input compared to alternative extrac-
tion kits, including RecoverAll (Ambion). PCA for all
human non-coding RNAs revealed substantial variation
between the two extraction kits. Thus, the results of the
PCA indicate that a particular tumor sample is more
distantly separated from itself when RNA is extracted
with a different kit, as compared with tumor samples
from different patients when RNA is extracted with the
same kit. As a consequence, the two RNA extraction
procedures are not interchangeable within either an
experiment, or across different experiments that are per-
formed for validation purposes.
Comparison of the FlashTag Biotin and FlashTag Biotin
HSR labeling kits
Mean intensity and the number of detected probes and
probe sets, in RNA preparations labeled with the Flash-
Tag Biotin HSR labeling kit, all exceed those in RNA
preparations labeled with the original FlashTag Biotin
labeling kit. PCA for all human non-coding RNAs
revealed substantial variation between the two labeling
kits. The results of the PCA indicate that a particular
tumor sample is more distantly separated from itself
when RNA is labeled with a different kit, as compared
to tumor RNA samples from different patients labeled
with the same kit. Within-kit variance for the FlashTag
Biotin labeling kit was very small compared to the
FlashTag Biotin HSR labeling kit. The small variance for
the FlashTag Biotin labeling kit may be a consequence
of a compressed mean (and variance) in signal intensity
(figure 12), in addition to a reduced detection of probes
and probes sets with this kit compared to the FlashTag
Biotin HSR labeling kit (figure 13), when the same sam-
ples were processed. As a consequence, the two RNA
labeling procedures are not interchangeable either
within an experiment, or across different experiments
that are performed for validation purposes.
Comparisons of Assays I & II
By comparing assay I and assay II using a profile of
fixed size (i.e. 30 non-coding RNAs) for each assay, and
performing 1000 Monte Carlo simulations, a signifi-
cantly better performance of assay II (62.6%) was
observed as compared to assay I (60%). The accuracy of
the final profiles (after performing nested LOOCV) for
assay I and assay II were 63% and 73% respectively,
again pointing to a better performance of assay II. A
Kaplan-Meier time-to recurrence plot using data from
assay II demonstrated a clear and significant separation
of the predicted “recurrence” and “no recurrence”
groups (LOOCV accuracy of 73%, p < 0.001; figure 16).
The miRNA list obtained on one assay, however, could
Table 5 Prognosticator calls (0 ="no recurrence” or 1 = “recurrence”) were examined for varying RNA input amounts
(a single T2 NSCLC specimen), ATP-mix dilutions (two NSCLC specimens), chip lot numbers (a single T2 NSCLC
specimen), RNA extraction kits (four NSCLC specimens; HP = HighPure, Roche &RA = RecoverAll, Ambion) and RNA
labeling kits (four NSCLC specimens; F = Flashtaq and FH = Flashtaq HSR, Genisphere) for selected samples using the
prognostic profile of assay II.
RNA amount Call Recurrence Chip lot Call Recurrence Labeling kit Call Recurrence
80 ng 1 - Lot x 1 - RPCI-18 - F1 1 No
100 ng 1 - Lot x 1 - RPCI-29 - F2 1 Yes
100 ng 1 - Lot y 1 - RPCI-57 - F3 1 No
100 ng 1 - RPCI-64 - F4 1 No
160 ng 1 -
400 ng 1 - RNA extraction kit RPCI-18 - FH1 0 No
640 ng 1 - RPCI-29 - FH2 0 Yes
KH882A9 - HP 0 - RPCI-57 - FH3 0 No
ATP-mix dilution KH22716D3 - HP 0 - RPCI-64 - FH4 0 No
KH24218B4 - HP 0 -
A-504; 1:50 0 - KH24935B5 - HP 0 -
A-504; 1:150 0 -
A-504; 1:500 0 - KH882A9 - RA 0 -
B-652; 1:50 0 No KH22716D3 - RA 0 -
B-652; 1:150 0 No KH24218B4 - RA 0 -
B-652; 1:500 0 No KH24935B5 - RA 0 -
Data for recurrence was available only for the test of labeling kit and for one sample used to test ATP-mix dilution.
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not predict NSCLC samples profiled using the other
assay adding to the importance of extraction and label-
ing kits on performance of miRNA based classifiers. The
observed accuracy of assay II was lower compared to an
assay developed using the Exiqon platform that demon-
strated an accuracy of 83%, in spite of the same patient
samples being used in both studies [6]. This may in part
be due to the larger number of samples being assayed in
the study using the Exiqon platform [6]. Even though
the profiles of the two platforms are not identical, the
assay in Patnaik et al. [6] and assay II maintained a high
accuracy, which is consistent with the MAQC studies
that demonstrated that data quality from single- and
two color platforms was essentially equivalent [20].
Impact of the analytical conditions on the robustness of
the prognosticator
The prognosticator calls (i.e. “recurrence” or “no recur-
rence”) for selected samples under varying analytical con-
ditions (table 5) were consistently independent of the
RNA input amount, ATP-mix dilution, chip lot number
and RNA extraction method being used. In contrast, the
calls were not robust to changes in labeling method.
Overall, the results support that labeling method (figure
14 and 15) and possibly also RNA extraction method,
due to large variation in PCA (figure 10 and 11), must be
held constant in order to provide for consistent results.
Since both of these variables differed between assay I and
assay II, changing each of them, or both, in general may
prevent a miRNA list obtained in one assay from being
able to predict NSCLC samples profiled using another
assay, as we found in this study.
Conclusions
In this study, we demonstrate that some analytic vari-
ables are important for the variation in assay perfor-
mance while others are not. Thus, careful optimization
that address all analytical steps and variables can facili-
tate the introduction of microRNA arrays for prediction
of relapse in stage I non-small cell lung cancer
(NSCLC). In result, stratification of patients with stage I
disease can be improved by prediction of relapse after
surgery, potentially allowing to direct intensive surveil-
lance and/or adjuvant therapy toward patients at high
risk of relapse (figure 16).
Methods
Patients and Tissue Specimens
Patient tumor samples were collected retrospectively
from Roswell Park Cancer Institute (RPCI), Buffalo, NY
and from Aarhus and Odense University Hospitals in
Denmark. The use of all included samples in this study
was approved by the institutional review board at Roswell
Park Cancer Institute, and, in Denmark, by Den
Videnskabsetiske Komité. The study was conducted in
accordance with the Helsinki declaration. In total 75
NSCLC specimens were included in the study. These
comprised 68 stage I NSCLC from a US cohort collected
and treated at RPCI [6] and seven NSCLC specimens col-
lected in Denmark. Clinical data were obtained only for
the US cohort, from the tumor registry at RPCI and
through chart reviews [6]. Approximately half of the
patients from the US cohort were known to have had a
recurrence. The recurrence-free cases were followed for
at least 32 months, with approximately half of them fol-
lowed for at least 5 years [6]. For the US specimens and
for two Danish specimens, tissue cores were sampled
from FFPE tissue blocks from areas with > 70% tumor
cell content (as verified by HE-stain), and subsequently
cores were re-embedded in paraffin. For the remaining
four FFPE specimens, tissues sections (20 μm thick) were
obtained for the comparison of the two RNA extraction
kits. One NSCLC specimen was collected within two
hours of surgery and was preserved in RNAlater
(Ambion, Inc 2130 Woodward St. Austin, TX) with
approval by Den Videnskabsetiske Komité in Denmark
and with informed consent obtained from the patient.
RNA extraction
In a PubMed http://www.ncbi.nlm.nih.gov/pubmed
search using the search terms “miRNA” AND “Cancer”
AND “FFPE”, 33 publications were retrieved covering
the period from 2009 to 2011. Of these, 16 publications
described the use of global miRNA profiling, and in
over half of these (i.e. in 9 studies), RNA was extracted
using the RecoverAll kit (Ambion). In the present study
we compared two different RNA extraction methods. In
addition to the widely used RecoverAll kit (”RA Kit“,
Ambion), we included the High Pure miRNA Isolation
Kit (”HP Kit“, Roche Applied Science, 68298 Mannheim,
Germany). For the HP Kit, RNA was extracted from
deparaffinized and proteinase K-treated FFPE core tis-
sues (20-40 mg) or sections according to the manufac-
turer’s instructions. In approximately one-third of the
cases, RNA preparations were of poor quality. Conse-
quently, RNA was extracted again from FFPE tissue. For
the RA Kit, RNA was extracted from deparaffinized and
protease-treated FFPE core tissues (20-40 mg) or sec-
tions with on column DNAse digestion according to the
manufacturer’s instructions. RNA concentration and
quality was assessed by absorbance spectrometry and
electrophoresis using the NanoDrop (Thermo Fisher
Scientific, Wilmington, DE) and Bioanalyzer 2100 (Agi-
lent Technologies) instruments.
Labeling of RNA
Two different RNA labeling methods were compared in
this study; the FlashTag™ Biotin RNA Labeling Kit
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(Genisphere, PA), and the new HSR version of the same
kit were used according to the manufacturer’s instruc-
tions unless otherwise stated. Poly (A)-tailing: 100-800
ng RNA including the small RNA species was used as
starting material for the polyA-tailing reaction with dif-
ferent ATP-mix dilutions (from 1:10-1:500). Poly (A)-
tailing was performed at 37°C for 15 minutes (GeneAmp
PCR System 9700, Applied Biosystems, Foster City, CA).
Ligation: Using the entire reaction product from the
poly (A) tailing reaction, a biotin-labeled 3DNA® den-
drimer was ligated to the poly (A) tails using a T4 DNA
Ligase and incubated at 25°C for 30 minutes (GeneAmp
PCR System 9700, Applied Biosystems®) following the
manufacturer’s instructions.
Hybridization
Of the 16 studies from the PubMed http://www.ncbi.
nlm.nih.gov/pubmed search describing global miRNA
profiling, 12 studies used six different commercially
available platforms and the remaining four studies used
different custom platforms. Between 365 and 847
human miRNAs were profiled using from 20 ng to 5 ug
totalRNA as input. In the present study we used the
platform with the broadest coverage, i.e. the Afymetrix
GeneChip® miRNA Array that interrogates 847 human
miRNAs and about an equal number of small non-cod-
ing RNAs. Hybridization washing and staining were per-
formed using the Affymetrix GeneChip Hybridization,
Wash and Stain Kit (Affymetrix, CA). Briefly, the hybri-
dization cocktail containing the biotin labeled RNA was
heated to 99°C for 5 minutes and then to 45°C for 5
minutes (GeneAmp PCR System 9700, Applied Biosys-
tems®) before loading onto the Affymetrix probe array
cartridge (GeneChip® miRNA Array). The volume of
the hybridization cocktail loaded on the chip was chan-
ged from 100 ml to 80 ml in order to improve move-
ment/flow of the cocktail in the hybridization chamber,
ensuring a better and more even hybridization process.
Thus, in effect only 80% of the labeled RNA was placed
on the chip. The probe array was incubated for 17
hours at 48°C with constant rotation (60 r.p.m.). The
probe array was incubated for 17 h at 48°C at constant
rotation (60 r.p.m.). The biotin labeled RNA was stained
with a streptavidin-phycoerythrin conjugate and the sig-
nals amplified using a biotinylated goat antibody against
streptavidin. Finally, the samples were stained with a
streptavidin-phycoerythrin conjugate.
Scanning
The probe arrays were scanned using a confocal laser-
scanning microscope (Affymetrix GCS3000Dx2). The
readings from the quantitative scanning were analyzed
using the Affymetrix Molecular Diagnostics Software
(AMDS). The microarray data was deposited in the
Array Express public database http://www.ebi.ac.uk/
arrayexpress/ and has been assigned accession number
E-MTAB-618 (under experiment name: Laboratory
assays for prediction of relapse in stage I non-small cell
lung cancer (NSCLC)).
RNA input amount
For comparisons, RNA was extracted from a sample col-
lected under conditions where RNA degradation is
expected to be minimal. Thus, a sample of a T2 NSCLC
post-resection surgical specimen was collected and pre-
served in RNAlater (Ambion) within 2 hours of after
surgery. RNA was subsequently extracted using the HP
Kit. The effect of varying RNA input amounts (80, 100,
160, 400 and 640 ng) for hybridization was examined. In
addition, RNA was prepared from ten stage I NSCLC
surgical FFPE specimens using the HP Kit (100 and 600
ng) and these samples were labeled and hybridized to
miRNA arrays. Signal intensities were examined on the
chip using laser scanning microscopy. Background
intensity ranged from 31 to 36 and was unrelated to the
amount of input RNA (results not shown). Subtraction
of background intensities did not affect the results (data
not shown).
ATP-mix dilution
The effect of different ATP-mix dilutions (1:10; 1:50
and 1:100) was examined using 100 ng RNA extracted
from a single NSCLC specimen using the HP Kit and
labeled using the FlashTag™ Biotin RNA Labeling Kit
(Genisphere). In addition, different ATP-mix dilutions
(1:50; 1:150 and 1:500) were examined using two pre-
parations of 600 ng RNA extracted from two different
NSCLC FFPE specimens using the RA Kit and labeled
using the FlashTag™ Biotin HSR RNA Labeling Kit
(Genisphere).
Different chip lot numbers
Correlations in signal intensities were examined across
two different lots of arrays that were hybridized (in tri-
plicates) to 100 ng of labeled RNA (FlashTag™ Biotin
RNA Labeling Kit, ATP-mix dilution 1:50) from of a sin-
gle RNA preparation of a T2 NSCLC tumor using the
HP Kit.
Comparisons of two different RNA extraction kits
The High Pure miRNA Isolation Kit (”HP Kit “, Roche)
and RecoverAll (”RA Kit”, Ambion) extraction methods
were compared in an RNA extraction experiment with
four FFPE NSCLC specimens. From each specimen, 20
sections (20 mm thick) were cut, every other slide being
used for one extraction method and the remaining slides
for the other. For each extraction method, 1000 ng RNA
of each specimen was polyadenylated (ATP-mix dilution
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1:50) and labeled with biotin using the FlashTag™ Bio-
tin HSR RNA Labeling Kit (Genisphere, PA).
Comparisons of two different labeling kits
The FlashTag™ Biotin RNA Labeling Kit (Genisphere),
and the new HSR version of this kit were compared in
an RNA labeling experiment using RNA from four
NSCLC specimens from the RPCI cohort extracted
using the HP Kit. For each labeling kit, 600 ng RNA
from each specimen was polyadenylated (ATP-mix dilu-
tion 1:50) and labeled with biotin.
Assay I and II for prognostication in stage I NSCLC
For assay I, total RNA including small RNA was
extracted from 68 stage I NSCLC specimens using the
High Pure miRNA Isolation Kit (Roche) and 600 ng was
labeled using the FlashTag™ Biotin RNA Labeling Kit
(Genisphere). For assay II, total RNA including small
RNA was extracted from 63 of the 68 stage I NSCLC
specimens using RecoverAll (Ambion) and 600 ng was
labeled using the FlashTag™ Biotin HSR RNA Labeling
Kit (Genisphere).
Prognostic profile based on non-coding small RNA
species
We tested the performance of a SVM classifier on both
assays using a Monte Carlo approach. First, two-thirds
of a data set was randomly chosen and used as a train-
ing set. Second, training was done by setting the num-
ber of features (i.e. non-coding RNAs) to 30, chosen
according to a highest t statistic, MCRestimate package
[21], in a LOOCV-loop. The 30 most frequent features
were used for training of the SVM classifier. Third, per-
formance was measured on one-third of the data set left
out. Finally, the above procedure was repeated 1000
times. A nested LOOCV approach was further used to
identify the optimal number of non-coding RNAs in the
following way: First, a test sample was held out in the
outer loop (leaving N-1 samples). In the inner loop
LOOCV on N-1 samples was used to determine the
accuracy for a range of selected features. Here, features
were first selected based on the highest t statistic men-
tioned above. Next, selected features were used as input
to the SVM classifier to classify each left out sample in
turn. Subsequently, the number of features yielding the
highest accuracy was used to classify the test sample
that was held out in the outer loop. Ultimately, the
most frequent number of features yielded the chosen
prognostic profile.
Impact of analytical conditions on the robustness of the
prognosticator
To qualify the impact of any variances in the analytical
conditions of the assay, the calls (i.e. “recurrence” or “no
recurrence”) of the prognosticator were examined after
varying RNA input amount, ATP-mix dilution, chip lot
numbers, RNA extraction kit and RNA labeling kit for
eleven selected NSCLC samples. The prognosticator was
trained using either 68 (assay I) or 63 (assay II) stage I
NSCLC samples using a SVM classifier and the identi-
fied prognostic profiles of each assay. Second, the
trained SVM classifier was used to predict the outcome
and thus examine the robustness of the prognosticator.
Statistical analysis and Bioinformatics analysis
For testing the effects of RNA amount; ATPmix dilu-
tion; extraction kit and labeling kit on signal intensity,
background intensity, the numbers of detected probes
and probe sets, arrays were pre-processed using Affyme-
trix miRNA QC Tool 1.0.33 (with workflow set to
“default”). T-tests and ANOVA, assuming equal var-
iances were performed using the R software package
[22]. For correlation analysis, data normalization was
performed using the justRMA procedure in Bioconduc-
tor [21] generating expression indexes (log with base 2)
for all human features on the Affymetrix GeneChip
miRNA Arrays. Principal component analysis (PCA) was
performed using all human non-coding RNAs and the
extracted signature for prognostication. For the prognos-
tic profiles we used the raw miRNA data without back-
ground correction. We used perfect match probes only
and summarized with average difference.
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